Peptides Weekly – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Peptides Weekly

Patrick · Nerra Network

Health & Fitness

Science

Frequency: 1 episode/5d. Total Eps: 4

What peptides are, what the evidence actually shows, and what is approved, investigational or unregulated. Every Thursday: the week in peptide science and regulation, and one peptide explained properly — mechanism, studies, status, risks. Education only; never dosing, sourcing or protocols, and never medical advice. AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production.

Read moreCollapse

Site

RSS

Apple

Data updated on 11/10/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇨🇦 Canada - Medicine
11/10/2026
#92

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.sciencedirect.com/science/article/pii/S0196978126000598?dgcid=rss_sd_all
1 share

https://www.washingtonpost.com/health/2026/10/07/trump-administration-paving-way-temporary-sale-some-unapproved-peptides/
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 68%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Ep 4: Unapproved peptides could reach temporary sale while treatment claims are still not fully…

Season 1 · Episode 4

Thursday, October 8, 2026 • Duration 08:19

Peptides Weekly Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. What You Need to Know: Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. Political Wire, quoting The Washington Post, describes a drafting process for previously restricted peptides, not a completed approval and not a patient trial. ... Sources: washingtonpost.com · stocktwits.com · ascopost.com · amp.sacbee.com · foodnavigator.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Read moreCollapse

Ep 3: Nail detachment was over four times more common in people using GLP-1 drugs.

Season 1 · Episode 3

Thursday, October 1, 2026 • Duration 09:29

Peptides Weekly Nail detachment was over four times more common in people using GLP-1 drugs. What You Need to Know: A controlled study found nail detachment more than four times as often among people using GLP-1 drugs. The same week brought a muscle-loss trial beside semaglutide, a randomized look at how semaglutide meets the kidney, and two reminders that a population trend and a protein-design paper are not treatment results. ... Sources: medicalxpress.com · reuters.com · nature.com · t.co AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Read moreCollapse

Ep 2: Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study.

Season 1 · Episode 2

Thursday, September 24, 2026 • Duration 07:17

Peptides Weekly Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study. What You Need to Know: A retrospective analysis found nutritional deficiencies in almost 17 percent of children prescribed GLP-1 receptor agonists for weight loss or diabetes. The finding comes from claims data and highlights a measurable gap in monitoring for younger patients. ... Sources: sciencedaily.com · yaledailynews.com · euractiv.com · velo.outsideonline.com · sciencedirect.com · europepmc.org AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Ep 1: Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were…

Season 1 · Episode 1

Wednesday, September 23, 2026 • Duration 06:20

Peptides Weekly Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were released this week. What You Need to Know: Novo Nordisk reported new phase 3 data on an amylin-based candidate. A pair of randomized trials found oral semaglutide did not slow progression in mild Alzheimer’s disease. ... AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Read moreCollapse

Peptides Weekly – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Peptides Weekly – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other15

ScienceDirect1

The Washington Post1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other15

ScienceDirect1

The Washington Post1